8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Cancer & Tumors869 citations

Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H

Bioeffects Seen

Authors not listed · 1992

View Original Abstract
Share:

Cancer research reveals how immune regulatory cells create therapeutic challenges, providing context for understanding EMF's potential immune system impacts.

Plain English Summary

Summary written for general audiences

This 2020 review study examined regulatory T cells (Tregs) in cancer environments, focusing on how these immune cells suppress the body's natural cancer-fighting responses. The researchers analyzed various molecular pathways and receptors that control Treg function and evaluated potential therapeutic strategies. The findings highlight the challenge of targeting these cells for cancer treatment without compromising the immune system's normal protective functions.

Why This Matters

While this cancer immunology research doesn't directly address EMF exposure, it provides crucial context for understanding how electromagnetic fields might influence immune function and cancer development. The study's focus on regulatory T cells is particularly relevant because these immune cells play a dual role - they prevent autoimmune diseases but also help tumors evade immune detection. Several EMF studies have suggested that radiofrequency radiation can alter immune cell behavior and potentially suppress natural tumor surveillance mechanisms. The complex balance between immune tolerance and cancer protection that this research describes becomes especially important when considering how chronic EMF exposure might tip that balance in favor of tumor growth.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (1992). Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H.
Show BibTeX
@article{chou_c_k_a_guy_ll_kunz_rb_johnson_jj_crowley_and_j_h_ce4874,
  author = {Unknown},
  title = {Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H},
  year = {1992},
  doi = {10.1186/s12943-020-01234-1},
  url = {http://www.saferemr.com/2016/06/national-toxicology-program-not-first.html},
}

Quick Questions About This Study

Regulatory T cells (Tregs) are immune cells that normally prevent autoimmune reactions but unfortunately also suppress the body's natural ability to detect and destroy cancer cells, making tumors harder to treat.
Tregs share many molecular pathways with beneficial immune cells and are essential for preventing autoimmune diseases, so eliminating them could cause serious immune system dysfunction throughout the body.
Foxp3 is the master control protein that defines regulatory T cells. It acts like a molecular switch that determines whether immune cells will suppress or activate immune responses against potential threats.
Costimulatory and inhibitory receptors on Tregs act like accelerator and brake pedals, controlling how strongly these cells suppress immune responses and representing potential targets for cancer immunotherapy development.
Researchers are developing combination therapies using checkpoint inhibitors and other approaches to selectively reduce Treg activity specifically within tumors while preserving their protective functions elsewhere in the body.